Surgical Treatment of Renal Cell Carcinoma in the Immunocompromised Transplant Patient

Urology

Volumn 75, Issue 6, 2010, Pages 1373-1377

  Tollefson, Matthew K ^a   Krambeck, Amy E ^a   Leibovich, Bradley C ^a   Blute, Michael L ^a   Chow, George K ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLMALONIC ACID; RAPAMYCIN; STEROID; TACROLIMUS;

ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; DISTANT METASTASIS; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NEPHRECTOMY; NEPHRON SPARING SURGERY; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SKIN CANCER;

AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TRANSPLANTATION IMMUNOLOGY;

EID: 77952742173     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.06.085     Document Type: Article

References (30)

1. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 12 (1993) S328-S336
2. Adami J., Gabel H., Lindelof B., et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 89 (2003) 1221-1227
3. Vajdic C.M., McDonald S.P., McCredie M.R., et al. Cancer incidence before and after kidney transplantation. J Am Med Assoc 296 (2006) 2823-2831
4. Krikorian J.G., Anderson J.L., Bieber C.P., et al. Malignant neoplasms following cardiac transplantation. J Am Med Assoc 240 (1978) 639-643
5. Cecka J.M. The OPTN/UNOS Renal Transplant Registry. Clin Transpl (2005) 1-16
6. Deuse T., Haddad F., Pham M., et al. Twenty-year survivors of heart transplantation at Stanford University. Am J Transplant 8 (2008) 1769-1774
7. Avitzur Y., De Luca E., Cantos M., et al. Health status ten years after pediatric liver transplantation-looking beyond the graft. Transplantation 78 (2004) 566-573
8. Lindelof B., Sigurgeirsson B., Gabel H., et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143 (2000) 513-519
9. Kyllonen L., Salmela K., and Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int 13 suppl 1 (2000) S394-S398
10. Cowlrick I., Delventhal H., Kaipainen K., et al. Three-year follow-up of malignancies in tacrolimus-treated renal recipients-an analysis of European multicentre studies. Clin Transpl 22 (2008) 372-377
11. + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 14 (2008) 5884-5892
12. Thompson R.H., Gillett M.D., Cheville J.C., et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101 (2004) 17174-17179
13. Crispen P.L., Sheinin Y., Roth T.J., et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 14 (2008) 5150-5157
14. Mohsin N., Budruddin M., Kamble P., et al. Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus. Transplant Proc 39 (2007) 1267-1271
15. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: prevention and treatment. Nephrol Dial Transplant 17 suppl 4 (2002) 32 34-36
16. Thompson R.H., Leibovich B.C., Lohse C.M., et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 177 (2007) 477-480
17. Frank I., Blute M.L., Cheville J.C., et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168 (2002) 2395-2400
18. Goldfarb D.A. Nephron-sparing surgery and renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. J Intern Med 243 (1998) 563-567
19. Steinbach F., Novick A.C., and Shoskes D. Renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Urology 44 (1994) 760-763
20. Otley C.C., Coldiron B.M., Stasko T., et al. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 137 (2001) 459-463
21. Tang S., Cheng I.K., Leung V.K., et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 39 (2003) 875-878
22. Khariwala S.S., Kjaergaard J., Lorenz R., et al. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 116 (2006) 814-820
23. Namba R., Young L.J., Abbey C.K., et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 12 (2006) 2613-2621
24. Tessmer C.S., Magalhaes L.V., Keitel E., et al. Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 82 (2006) 1792-1793
25. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581-589
26. Mannami M., Mannami R., Mitsuhata N., et al. Last resort for renal transplant recipients, "restored kidneys" from living donors/patients. Am J Transplant 8 (2008) 811-818
27. Neipp M., Schwarz A., Pertschy S., et al. Accidental transplantation of a kidney with a cystic renal cell carcinoma following living donation: management and 1 yr follow-up. Clin Transpl 20 (2006) 147-150
28. Mitsuhata N., Ito S., Mannami M., et al. Donor kidneys with small renal cell cancer or low-grade lower ureteral cancer can be transplanted. Transplantation 83 (2007) 1522-1523
29. Buell J.F., Hanaway M.J., Thomas M., et al. Donor kidneys with small renal cell cancers: can they be transplanted?. Transplant Proc 37 (2005) 581-582
30. Thompson R.H., Boorjian S.A., Lohse C.M., et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 179 (2008) 468-471 Discussion: 472-473